



EPI WATCH

Monthly Epidemiology and Preparedness Newsletter

November 2014

Florida Department of Health in Pinellas County

205 Dr. M.L King Street N. St. Petersburg, FL 33701 (727) 824-6900 www.PinellasHealth.com

Division of Disease Control and Health Protection 8751 Ulmerton Road

8751 Ulmerton Roa Largo, FL 33771 (727) 524-4410

Director

Claude Dharamraj, MD, MPH, FAAP

claude.dharamraj@flhealth.gov

Editor

JoAnne Lamb, MPH joanne.lamb@flhealth.gov

For more information, or to add your e-mail address to the distribution list, please contact the Editor.

Disease Reporting

To report diseases and clusters of illness (other than TB/STD/HIV/AIDS)
Phone: (727) 507-4346
Fax: (727) 507-4347




For TB, STD or HIV/AIDS Reporting

Phone: (727) 824-6932

Animal Bite Reporting Phone: (727) 524-4410 x7665

World AIDS Day

December 1, 2014



Since 1988, December 1st has marked the global world calendar as "World AIDS Day." World AIDS Day is celebrated every year to raise awareness about HIV/AIDS and to demonstrate international solidarity in the face of the pandemic. UNAIDS (the Joint United Nations Program on HIV/AIDS) has elected to keep the theme "Getting to ZER0! 0 New HIV Infections, 0 Discrimination, 0 AIDS Related Deaths" until 2015.

The Florida Department of Health in Pinellas County, along with several local organizations, are hosting an event in Downtown St. Petersburg at Williams Park from Noon to 4:00 PM on Monday, December 1, 2014. Participants are offered free food, HIV and hepatitis counseling and testing, and routine health screenings.

Ebola Virus Disease (EVD): Travelers

The Centers for Disease Control and Prevention (CDC) issued a Warning, Level 3 travel notice for three countries, Guinea, Liberia, and Sierra Leone, and advised U.S. citizens to avoid all nonessential travel to those destinations. All air travelers entering the United States who have been in Guinea, Liberia, or Sierra Leone are being routed through five U.S. airports (New York's JFK International, Washington-Dulles, Newark, Chicago-O'Hare, and Atlanta) for enhanced entry screening.



Entry screening helps to prevent further spread of Ebola and protect the health of all Americans by identifying travelers who may be sick or exposed to Ebola and by ensuring that these travelers are directed to appropriate care. These inbound

travelers receive Check and Report Ebola (CARE) Kits that contain further information about Ebola. This kit includes a health advisory infographic about monitoring for Ebola symptoms for 21 days, pictorial description of symptoms, a thermometer with instructions for how to use it, a symptom log, and a wallet-sized card that reminds travelers to monitor their health and provides information about who to call if they have symptoms. (More information about CARE Kits is available here: http://www.cdc.gov/media/DPK/2014/Ebola-Care-Kit.html).

State and local health departments are working with the CDC to identify travelers entering their jurisdictions to ensure monitoring is completed appropriately and the proper public health measures are taken. On October 25, 2014, Florida Governor, Rick Scott, signed an Executive Order mandating twice-daily 21-day health monitoring for people returning from CDC designated Ebola-affected areas.

At this time, there are no cases or suspected cases of EVD in Florida. However, planning and preparations are ongoing as the situations in West Africa and the United States evolve.

If you have questions or concerns, please contact the Epidemiology Program at 727-507-4346. For the most up to date information on the EVD situation and guidance, visit the Centers for Disease Control and Prevention website: http://www.cdc.gov/vhf/ebola/index.html.

Pre-exposure Prophylaxis (PrEP) for HIV Prevention

By Christian Spears, MSW, MPH



In May 2014, the Centers for Disease Control and Prevention (CDC) and the US Public Health Institute released clinical practice guidelines for the administration of Pre-exposure Prophylaxis, better known as PrEP. When the drug is taken consistently, the treatment along with condoms has proven to be effective in preventing HIV infection in high-risk HIV-negative patients. In 2012, Truvada, a combination of Viread (tenorfovir) and Emtriva (emtricitabine), was the antiretroviral drug approved by the US Food and Administration (FDA) for PrEP.

PrEP was used in several national and international clinical trials that evaluated outcomes among heterosexual women and men, gay and bisexual men, and drug users who had been exposed to

HIV through injection drug use or sex. All of the studies demonstrated up to a 92% lower risk of acquiring the HIV infection when medicines were taken once a day consistently and a 3 month test was obtained. The treatment has been recommended by federal guidelines for individuals who are HIV-negative with multiple high-risk sex partners and no reported use of condoms. Post-exposure prophylaxis (PEP) is still available to be taken within 72 hours of a high risk exposure, such as unprotected sex, sexual assault, or needle-sharing during injection drug use.

There were early concerns regarding PrEP, including drug resistance of those who may become infected with HIV, cost, side effects, poor drug adherence, and regimen duration. To address some of these issues, Phase II clinical trials have been initiated for new drugs called long-acting injectable antiretroviral therapy. Once the drugs are injected, they remain effective in the body between 12-28 weeks. This alter-

native treatment includes 2 injections per year as opposed to a daily pill. Human trials will begin later this year.

HPTN 052 is the most recent study designed to evaluate the effects of immediate or delayed use of antiretroviral therapy by HIV-exposed negative partners. Studies have proved that sexual transmission of HIV was reduced by more than 96% in HIV-serodiscordant couples. However, all but one of the couples involved in the study were heterosexual.

CDC is leading PrEP awareness and delivery efforts by supporting the new recommendations and provider's supplement. Pilot

experiments are being physically implemented at four federally qualified health centers to study costs and requirements, as well as, providing program guidance and webinars for state and local health departments. Healthcare providers and other groups also continue to play a significant role in providing PrEP and raising awareness in at-risk communities.

More information regarding PrEP cane be found here: http://www.cdc.gov/hiv/pdf/guidelines/
PrePguidelines2014.pdf

Information about the HIV /AIDS Program at the Florida Department of Health in Pinellas County is available here: http://pinellas.floridahealth.gov/programs-and-services/infectious-disease-services/hiv-aids/index.html



Quick Facts about HIV/AIDS in Florida

- 2nd in the nation with newly reported HIV infections
- * 2nd in the nation with cumulative pediatric AIDS cases
- 3rd in the nation with 130,000 persons living with HIV disease
- 3rd in the nation with 105,000 persons living with AIDS disease
- Pinellas County is ranked 7th in Florida for HIV/AIDS cases

Information collected from: HIV Disease: United States vs. Florida Report,
FL Department of Health, Bureau of Communicable Disease, HIV/AIDS Section
http://www.floridahealth.gov/diseases-and-conditions/aids/surveillance/documents/fact-sheet/2013-us-vs-fl.pdf

Selected Reportable Diseases in Pinellas County

	Pinellas	Year-to-Date		Pinellas County Annual Totals		
Disease	October 2014	Pinellas 2014	Florida 2014	2013	2012	2011
A. Vaccine Preventable		•	•			
Measles						
Mumps			1			
Pertussis		19	664	17	10	10
Varicella	3	21	486	19	16	21
B. CNS Diseases & Bacteremias			400	10	10	
Creutzfeldt-Jakob Disease (CJD)			14		2	3
Meningitis (Bacterial, Cryptococcal, Mycotic)	1	2	102	5	6	7
	I		42	1	0	- 1
Meningococcal Disease		44		1		
S. Pneumoniae, Invasive Disease, Drug Resistant		11	348	24	16	22
S. Pneumoniae, Invasive Disease, Susceptible		11	365	11	25	11
C. Enteric Infections						
Campylobacteriosis	11	89	1884	63	59	83
Cryptosporidiosis	25	229	1677	19	29	19
Cyclosporiasis	20		30	5	1	2
E. coli Shiga Toxin (+)		6	147		8	2
Giardiasis	0					-
	8	35	1011	34	32	27
Hemolytic Uremic Syndrome (HUS)			6	1	_	
Listeriosis			36		5	3
Salmonellosis	34	178	5052	203	203	225
Shigellosis	1	19	2049	5	18	93
D. Viral Hepatitis						
Hepatitis A		2	94	6	4	5
Hepatitis B: Pregnant Woman +HBsAg	2	21	430	17	16	29
Hepatitis B, Acute	4	27	345	39	16	10
Hepatitis C, Acute	1	14	156	17	5	13
E. Vector Borne, Zoonoses						
Animal Rabies			78			2
Rabies, possible exposure	14	162	2375	193	201	217
Chikungunya Fever	3	10	342			
Dengue		1	80	2	3	1
Eastern Equine Encephalitis			1			<u> </u>
Lyme Disease		4	119	8	6	9
Malaria		2	.	1	_	1
St. Louis Encephalitis			2	<u>'</u>	2	<u>'</u>
West Nile Virus			20			
F. Others			20			
AIDS**	14	126	n/a	118	130	123
HIV**	34	239	n/a n/a	187	177	189
Chlamydia	384	3232		4141	3812	3863
Gonorrhea			n/a	1424	1029	1034
	132	1061	n/a	1424	1029	1034
Hansen's Disease		-	6			-
Lead Poisoning: Children < 6 years:		5	130	4	2	4
Legionellosis	3	12	238	10	13	13
Mercury Poisoning		2	12			2
Syphilis, Total	14	160	n/a	114	141	132
Syphilis, Infectious (Primary and Secondary)	7	63	n/a	52	61	66
Syphilis, Early Latent	3	51	n/a	37	47	35
Syphilis, Congenital			n/a			1
Syphilis, Late Syphilis (Late Latent; Neurosyphilis)	4	46	n/a	25	33	30
Tuberculosis	3	21	n/a	30	17	9
Vibrio Infections	1	8	137	11	10	11
			101	- 11	10	

n/a = not available at this time. Blank cells indicate no cases reported. Reportable diseases include confirmed and probable cases only. All case counts are provisional. Data is collected from the Merlin Reportable Disease database, surveillance systems maintained at the Florida Department of Health in Plinellas County, and Florida CHARTS http://www.floridacharts.com/charts/default.aspx.

^{*}STD data in PRISM is continually updated. Please note, data from the previous month takes up to an additional month or more to be correctly updated.